Paying for blood donations: Still a risk?

Vox Sanguinis

Volumn 83, Issue 4, 2002, Pages 285-293

  Van der Poel, C L ^a   Seifried, E ^b   Schaasberg, W P ^c  

^a CENTRAL LABORATORY   (Netherlands)

^b Red Cross Blood Donor Service   (Germany)

^c STATISTICS NETHERLANDS   (Netherlands)

Author keywords

Blood safety; Paid donors; Volunteer donors

Indexed keywords

BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; DISEASE MARKER; ERYTHROCYTE; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INFECTION RISK; PREVALENCE; PRIORITY JOURNAL; PURIFICATION; REVIEW; RISK FACTOR; SAFETY; SCREENING TEST; THROMBOCYTE; VIRUS INACTIVATION;

BLOOD DONORS; BLOOD TRANSFUSION; FEES AND CHARGES; HUMANS; INFECTION; INFECTION CONTROL; RISK; VOLUNTARY PROGRAMS;

EID: 0036862028     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.2002.00239.x     Document Type: Review

References (45)

1. Commission Online: Successful Health Council on 15 November. Brussels, European Commission, 2001 (www.europa.eu.int/rapid/start/cgi/guesten.ksh?p_ action.gettxt=gt.../374|0]RAPIDElg=EN)
2. Scientific Committee on Medical Products and Medical Devices: Opinion on the Quality and Safety of Blood. SANCO/SCMPMD/2000/0005 Final. Luxembourg, SCMDMP, European Commission, 2000
3. Domen RE: Paid-versus-volunteer blood donation in the United States: A historical review. Transfus Med Rev 1995; 9:53-59
4. Strauss RG: Blood donations, safety and incentives. Transfusion 2001; 41:165-167
5. Eastlund T: Monetary blood donation incentives and the risk of transfusion-transmitted infection. Transfusion 1998; 38:874-882
6. United States General Accounting Office: Blood Plasma Safety: Plasma Product Risks Are Low If Good Manufacturing Practices Are Followed. Washington DC, GAO, 1998 (WWW.GAO/HEHS-98-205)
7. Seifried E, Hitzler W: Status of NAT screening for HCV, HIV and HBV. Experience in Germany. Infusionsther Transfusionsmed 2001; 28:231-232
8. Kühnl P, Seidl S, Stangel W et al.: Antibody to hepatitis C virus in German blood donors. Lancet 1989; 2:324
9. Schreiber GB, Busch MP, Kleinman SH et al.: The risk of transfusion transmitted viral infections. The Retrovirus Epidemiology Study. N Engl J Med 1996; 334:1685-1690
10. Strauss RG, Floss AS, Eckerman I et al.: Carefully selected, paid donors can serve as a source of safe blood. Transfusion 1986; 26:602
11. Strauss RG, Ludwig GA, Smith PJ et al.: Concurrent comparison of the safety of paid cytapheresis and volunteer whole blood donors. Transfusion 1994; 34:116-121
12. Fiedler H: How can the safety of different types of donors be compared? Transfusion 1995; 35:179-180
13. Saldanha J, Minor P: A sensitive PCR method for detecting HCV RNA in plasma pools, blood products, and single donations. J Med Virol 1994; 34:72-76
14. Paul-Ehrlich Institut: Bekanntmachung des Paul-Ehrlich-Instituts vom 25.2. über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis C-, und HIV-Infectionen bei Empfängern von Erythrozytenkonzentraten, Banz, no. 63 vom, Paul-Ehrlich Institut, Langen 1998:040497, S 4447 (www.pei.de/massnahm/erypcr.htm)
15. Sanchez AM, Ameti DI, Schreiber GB et al.: The potential impact of incentives on future blood donation behaviour. Transfusion 2001; 41:172-178
16. Clayton D, Hills M: Statistical Models in Epidemiology. Oxford, UK, Oxford University Press, 1993
17. Hellstern P, Bach J, Haubelt H et al.: The impact of the intensity of serial automated plasmapheresis and the velocity of deep-freezing on the quality of plasma. Infusionsther Transfusionsmed 2001; 28 (sonderheft): 62-63
18. Fiedler H: HIV seropositivity in paid blood donors. Lancet 1992; 339:551
19. Van der Poel CL, Ebeling F: Hepatitis C virus: epidemiology, transmission and prevention; in Reesink HW (ed.): Hepatitis C Virus. Current Studies in Hematology and Blood Transfusion, no. 62. Basel, Karger, 1998:208-236
20. Nelson KE, Vlahov D, Margolick J, Bernal M, Taylor E: Blood and plasma donations among a cohort of intravenous drug users. JAMA 1990; 263:2194-2197
21. Roth WK, Seifried E: Reducing the residual risk of transfusion-transmitted viruses: Minipools or single-donations NAT? Transfusion 2001; 41:845-846
22. Taswell HF: Directed, paid and self-donors; in Clark GM (ed.): Competition in Blood Services. Arlington, American Association of Blood Banks, 1987:137-148
23. Okochi K, Murakami S: Observations on Australia antigen in Japanese. Vox Sang 1968; 15:374-385
24. Goesser E, London T, Sutnick A et al.: Post-transfusion hepatitis and frequency of donor blood Australia antigen in population subgroups. Clin Res 1970; 18:380
25. Guardia J, Bacardi R, Hernandez JM, Martiniz JM: Screening blood donors for Au antigen. Lancet 1970; 2:465
26. Cherubin CE, Prince AM: Serum hepatitis specific antigen (SH) in commercial and volunteer sources of blood. Transfusion 1971; 11:25-27
27. Prince AM, Szmuness W, Woods KR, Grady GF: Antibody against serum hepatitis antigen. N Engl J Med 1971; 285:933-938
28. Szmuness W, Prince AM, Brotman B, Hirsch RL: Hepatitis B antigen and antibody in blood donors: An epidemiologic study. J Infect Dis 1973; 127:17-25
29. Froesner GG, Peterson DA, Holmes AW, Deinhardt FW. Prevalence of antibody to hepatitis B surface antigen in various populations. Infect Immun. 1975; 11:732-736
30. Seeff LB, Zimmerman HJ, Wright EC et al.: A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. Gastroenterology 1977; 72:111-121
31. Hernandez JM, Argelagues E, Canivell M: HTLV-III antibody in paid plasma donors in Spain. Lancet 1985; 1:1389
32. Hughes M, Lloyd J, Singleton J, Wagner I: HIV testing in California blood banks and plasma centers. First Quarter, 1989. California Department of Health Services. Calif AIDS Update 1989; 2:95-97
33. Abbott Laboratory: Special report: FDA workshop focuses on plasma collection. CCBC Newsletter 1993; 9:4
34. Sepulveda Amor J, de Lourdes Garcia M, Dominguez Torix JL et al.: Prevention of HIV transmission through blood and blood products: Experiences in Mexico. Bull Pan Am Health Organ 1989; 23:108-114
35. Chiron Corporation: Hepatitis C Virus Encoded Antigen (Recombinant C100-3). Data submitted to the United States Food and Drug Adminstration for licensure. Summary Basis for Approval. Emeryville, CA, Chiron Corporation, 1989
36. Canavaggio M, Leckie G, Allain JP et al.: The prevalence of antibody to HTLV-III in United States plasma donors and in United States and French hemophiliacs. Transfusion 1990; 30:780-782
37. Dawson G, Lesniewski R, Stewart JL et al.: Detection of antibodies to hepatitis C virus in U.S. blood donors. J Clin Microbiol 1991; 29:551-556
38. Wu RR, Mizokami M, Lau JY et al.: Seroprevalence of hepatitis C virus infection and its genotype in Lanzhau, Western China. J Med Virol 1995; 45:174-178
39. Dille BJ, Surowy TK, Gutierrez RA et al.: An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 1997; 175:458-461
40. Abbott Laboratory: Abbott laboratory report. CCBC Newsletter 1996; 3:8
41. Singh YN, Malaviya AN, Tripathy SP et al.: Human immunodeficiency virus in the blood donors of Delhi, India. J Acquir Immune Defic Syndr 1990; 3:152-154
42. Jha J, Banerjee K, Arankalle VA: A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India. J Viral Hep 1995; 2:257-260
43. Goodnough LT, Brecher MD, Kanter MH et al.: Transfusion medicine - Blood transfusion - First of two parts. N Engl J Med 1999; 340:438-447
44. European Community: Council Recommendation on the Suitability of Blood and Plasma Donors and the Screening of Donated Blood in the European Community. Official Journal of the European Communities 98/463/EC. Brussels, European Commission, 1998
45. Weusten JJAM, Van Drimmelen HAJ, Lelie PN: Mathematic modelling of the risk of HBV, HCV and HIV transmission by window phase donations not detected by NAT. Transfusion 2002; 42:537-548